Over kanserinde intraperitoneal kemoterapi esnasında gelişen katater ilişkili komplikasyonların yönetimi: İki olgu sunumu ve literatür derlemesi

Year 2018, Volume: 31 Issue: 2, 88 - 93, 05.06.2018

Gunsu Kımyon Comert Osman Turkmen Alper Karalok Derman Basaran Cigdem Kılıc Sevgi Koc Fulya Kayıkcıoglu Nurettin Boran

https://doi.org/10.5472/marumj.430817

Cited By: 3

Abstract

Bu çalışmada, over kanseri tanısıyla sitoredüktif cerrahiyi takiben

uygulanan intraperitoneal kemoterapi (İPK) esnasında meydana

gelen kateter ilişkili komplikasyona sahip iki hasta sunulmuştur.

Hastalardan birinde bağırsak perforasyonu gelişmiştir. Port

çıkarılmış ve kolostomi uygulanmıştır. Diğer hastada ise, kateterde

blokaj gelişmiş ve kateter boyunca uzanan fibröz adezyonun

serbestleştirilmesi ile komplikasyon yönetilmiştir. Kemoterapi

her iki olguda da gecikme olmaksızın 16 haftada tamamlanmıştır.

Seröz over kanserinde optimal sitoredüktif cerrahi sonrası İPK,

sağkalımı arttırarak umut vaad etmektedir. Klinik uygulamaya

adaptasyonu zorlaştıran nedenlerin başında gelen kateter ilişkili

komplikasyonlar kemoterapinin tamamlanmasında gecikme

olmaksızın yönetilebilmektedir.

Keywords

Over kanseri, Intraperitoneal kemoterapi, Kateter ilişkili komplikasyon

Management of catheter-related complications during intraperitoneal chemotherapy for ovarian cancer: Two case reports and review of the literature

Abstract

In this article, we presented two cases with catheter-related

complications that occurred during intraperitoneal chemotherapy

(IPC) following comprehensive cytoreductive surgery for ovarian

carcinoma. One of the patients had bowel perforation which was

managed by removing the port and creating a colostomy. The

other had catheter blockage that was managed by releasing the

catheter from the fibrous adhesion. Both patients completed all

cycles of chemotherapy without delay. IPC following optimal

cytoreductive surgery in serous ovarian carcinoma holds promise

to improve survival. Catheter-related complications are one of the

major barriers that health care centers experience with the use of

catheters in clinical practice. Yet, they can be managed without

having any delays in chemotherapy treatments.

Keywords

Ovarian cancer, Intraperitoneal chemotherapy, Catheter-related complication

References

• Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6:e1000114. doi: 10.1371/journal.pmed.1000114.
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:359- 86. doi: 10.1002/ijc.29210.
• Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2013; 130:12-8. doi: 10.1016/j. ygyno.2013.04.001.
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1):34-43. doi: 10.1056/NEJMoa052985.
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015; 33:1460-6. doi: 10.1200/jco.2014.55.9898.
• Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-7. doi: 10.1200/jco.2001.19.4.1001.
• Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007; 17:1-20. doi: 10.1111/j.1525-1438.2007.00809.x.
• National Cancer Institute. NCI clinical announcement in 2006: intraperitoneal chemotherapy for ovarian cancer Available from: [http://ctepcancergov/highlights/docs/clin_ annc_010506pdf]; Accessed 30/11/2017.
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5:649- 56.
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359-74.
• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-5. doi: 10.1056/nejm199612263352603.
• Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24:988-94. doi: 10.1200/ jco.2005.05.2456.
• Lesnock JL, Richard SD, Zorn KK, et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol 2010; 116:345-50. doi: 10.1016/j.ygyno.2009.11.009.
• Berry E, Matthews KS, Singh DK, et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009; 113:63-7. doi: 10.1016/j. ygyno.2008.12.035.
• Helm CW. Ports and complications for intraperitoneal chemotherapy delivery. BJOG 2012; 119:150-9. doi: 10.1111/j.1471-0528.2011.03179.x.
• Speyer JL, Myers CE. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 1980; 74:264-9.
• Pfeifle CE, Howell SB, Markman M, Lucas WE. Totally implantable system for peritoneal access. J Clin Oncol 1984; 2:1277-80. doi: 10.1200/jco.1984.2.11.1277.
• Black D, Levine DA, Nicoll L, et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 2008; 109:39-42. doi: 10.1016/j.ygyno.2007.12.004.
• Varney RR, Goel R, vanSonnenberg E, Lucas WE, Casola G. Delayed erosion of intraperitoneal chemotherapy catheters into the bowel. Report of two cases. Cancer 1989; 64:762-4.
• Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol 2012; 42:1013- 9. doi: 10.1093/jjco/hys129.
• Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecol Oncol 2009; 114:420-3. doi: 10.1016/j.ygyno.2009.05.036.
• Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 2008; 108:342-7. doi: 10.1016/j.ygyno.2007.10.004.
• Davidson SA, Rubin SC, Markman M, et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 1991; 41:101-6.
• Sakuragi N, Nakajima A, Nomura E, et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol 2000; 79:420-3. doi: 10.1006/gyno.2000.5979.
• Nanninga AG, Willemse PH, Boonstra H, De Vries EG. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int J Gynecol Cancer 1992; 2:107-10.
• Topuz E, Salihoglu Y, Aydiner A, et al. Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol 2000; 74:223-6.
• Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100:27-32. doi: 10.1016/j. ygyno.2005.11.013.
• Pendergrass M, Gordinier ME, Parker LP, Metzinger DS, Helm CW. Retraction of an intraperitoneal chemotherapy port: a case report and literature review. Int J Gynecol Cancer 2007; 17:1131-3. doi: 10.1111/j.1525-1438.2007.00910.x.
• Piccart MJ, Speyer JL, Markman M, et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985; 12(3 Suppl 4):90-6.